Список літератури, представлений в прототипі клінічної настанови 3 страница

250. Zanchetti A, Hansson L, Dahlof B, Elmfeldt D, Kjeldsen S, Kolloch R, Larochelle P, McInnes GT, Mallion JM, Ruilope L, Wedel H. Effects of indi­vidual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001;19:1149–1159. OS.

251. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001;12:218–225. RT.

252. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ,Sarti C, Staessen JA. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002;13:2213–2222. OS.

253. Segura J, Ruilope LM, Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22:1635–1639. RV.

254. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T. ALLHAT Collaborative Research Group. Cardiovascular out­comes in high-risk hypertensive patients stratified by baseline glomeru-lar filtration rate. Ann Intern Med 2006;144:172–180. OS.

255. Keith NH, Wagener HP, Barker MW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939;197: 332–343. OS.

256. Cuspidi C, Macca G, Salerno M, Michev L, Fusi V, Severgnini B, Corti C, Meani S, Magrini F, Zanchetti A. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examin­ation? Ital Heart J 2001;2:702–706. OS.

257. Dimmitt SB, West JN, Eames SM, Gibson JM, Gosling P, Littler WA. Use­fulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1989;1:1103–1106. OS.

258. Fuchs FD, Maestri MK, Bredemeier M, Cardozo SE, Moreira FC, Wainstein MV, Moreira WD, Moreira LB. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. J Hum Hypertens 1995;9:547–551. OS.

259. Wong TY, Klein R, Sharrett AR, Duncan BB, Couper DJ, Tielsch JM, Klein BE, Hubbard LD. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Commu­nities Study. JAMA 2002;287:1153–1159. OS.

260. Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, Hubbard LD, Mosley TH. ARIC Investigators. Atheroslerosis Risk in Communities Study. Retinal microvascular abnormalities and incident stroke: the Athero­sclerosis Risk in Communities Study. Lancet 2001;358:1134–1140. OS.

261. Martinez-Perez ME, Hughes AD, Stanton AV, Thom SA, Chapman N, Bharath AA, Parker KH. Retinal vascular tree morphology: a semi­automatic quantification. IEEE Trans Biomed Eng 2002;49:912–917.

262. Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, Chapman N, Stanton AV, Beevers G, Pedrinelli R, Parker KH, Thom SA. Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension. J Hypertens 2006;24:889–894.

263. Antonios TF, Singer DR, Markandu ND, Mortimer PS, MacGregor GA. Rar­efaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 1999;34:655–658. OS.

264. Noon JP, Walker BR, Webb DJ, Shore AC, Holton DW, Edwards HV, Watt GC. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997;99:1873–1879. OS.

265. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, Anton-Culver H, O’Leary DH. Silent brain infarction on magnetic reson­ance imaging and neurological abnormalities in community-dwelling older adults: the Cardiovascular Health Study. Stroke 1997;28: 1158–1164. OS.

266. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, Tyroler HA. Presence and severity of cerebral white matter lesions and hyper­tension, its treatment, and its control: The ARIC Study. Stroke 1996; 27:2262–2270. OS.

267. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Preva­lence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21–25. OS.

268. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L. Clinical correlates of white matter find­ings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27:1274–1282. OS.

269. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004;61:1531–1534. OS.

270. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotter­dam Scan Study. Stroke 2000;34:1126–1129. OS.

271. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Svanborg A. 15-year longitudinal study of blood pressure dementia. Lancet 1996;347:1141–1145. OS.

272. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: A 20-year follow-up of 999 men. Hypertension 1998;31:780–786. OS.

273. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846–1851. OS.

274. Mancia G. Role of outcome trials in providing information on antihyper-tensive treatment: importance and limitations. Am J Hypertens 2006; 19:1–7. RV.

275. Zanchetti A. Evidence-based medicine in hypertension: what type of evidence? J Hypertens 2005;23:1113–1120. RV.

276. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. Systo­lic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162: 2046–2052. CT.

277. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. Systo­lic Hypertension in Europe Investigators. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed anti-hypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004;22:847–857. CT.

278. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629–636. CT.

279. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1967;202:1026–1034. RT.

280. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Medical Research Council. BMJ 1985; 291:97–104. RT.

281. SHEP Collaborative Research Group. Prevention of stroke by antihyper-tensive drug treatment in older persons with isolated systolic hyperten­sion: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255–3264. RT.

282. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hyper­tension (STOP-Hypertension). Lancet 1991;338:1281–1285. RT.

283. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbid­ity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349–1354. RT.

284. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358: 1033–1041. RT.

285. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757–764. RT.

286. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, Ghadirian P, LeLorier J, Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;16:1237–1245. CT.

287. Liu L, Wang JL, Gong L, Liu G, Staessen JA. For the Syst-China Collabora­tive Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998;16:1823–1829. CT.

288. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986;293:1145–1151. RT.

289. MRC Working Party. Medical Research Council trial of treatmeant of hypertension in older adults: principal results. Br Med J 1992;304: 405–412. RT.

290. PATS Collaborative Group. Post-stroke antihypertensive treatment study. Chin Med J 1995;108:710–717. RT.

291. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980;69:725–732. RT.

292. Management Committee. The Australian therapeutic trial in mild hyper­tension. Lancet 1980;1:1261–1267. RT.

293. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527–1535. MA.

294. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055–1076. MA.

295. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355: 865–872. MA.

296. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, Ekbom T, Fagard R, Friedman L, Perry M, Prineas R, Schron E. The effect of anti-hypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta-analysis of individual patient data randomised controlled trials. Ann Intern Med 1997;126:761–767. MA.

297. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of pro-spectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410–1419. MA.

298. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LH. How strong is the evidence for use of beta-blockers as first-line therapy for hyperten­sion? Systematic review and meta-analysis. J Hypertens 2006;24: 2131–2141. MA.

299. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treat­ment Trialists’ Collaboration. Lancet 2000;356:1955–1964.

300. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihy-pertensive drug therapy in black patients. Ann Intern Med 2004;141: 614–627. MA.

301. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovas­cular events in high-risk patients. N Engl J Med 2000;342:145–153. RT.

302. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005;23:2157–2172. RT.

303. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782–788. RT.

304. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG, Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE, Seabra-Gomes R, Soler-Soler J, Weber S. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849–857. RT.

305. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005;23:641–648. CT.

306. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ. CAMELOT Investigators. Effect of antihy-pertensive agents on cardiorprovascular events in patients with coron­ary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217–2225. RT.

307. The PEACE trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New Engl J Med 2004;351:2058–2068. RT.

308. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003;21:875–886. RT.

309. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL StudyInvestigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861–869. RT.

310. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: 851–860. RT.

311. Pourdjabbar AM, Lapointe N, Rouleau J-L. Angiotensin receptor block-ers: Powerful evidence with cardiovascular outcomes? Can J Cardiol 2002;18(Suppl A):7A–14A. MA.

312. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) random­ised trial. Lancet 1998;351:1755–1762. RT.

313. Hypertension Detection, Follow-up Program. The effect of treatment on mortality in ‘mild’ hypertension: results of the Hypertension Detection, Follow-up Program. N Engl J Med 1982;307:976–980. RT.

314. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhi­bition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611–616. RT.

315. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new anti-hypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:175–1756. RT.

316. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359–365. RT.

317. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascularand microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–720. RT.

318. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER 3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT Jr, Xu S. African American Study of Kidney Disease, Hypertension (AASK) Study Group. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis. A Randomized Controlled Trial. JAMA 2001;285:2719–2728. RT.

319. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. African American Study of Kidney Disease, Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002;288:2421–2431. RT.

320. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albumi-nuria, retinopathy and stroke. Kidney Int 2002;61:1086–1097. RT.

321. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin independent diabetes and hyper­tension. N Engl J Med 1998;338:645–652. RT.

322. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366–372. RT.

323. The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients ran­domized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–2997. RT.

324. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ. CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003;289:2073–2082. RT.

325. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. SHELL Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003;12:160–167. RT.

326. NICS Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999;34:1129–1133. RT.

327. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S, Kawai C. Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;27:181–191. R T.

328. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. Second Australian National Blood Pressure Study Group. A com­parison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348: 583–592. RT.

329. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke pre­vention. Hypertension 2005;46:386–392.

330. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951–958. MA.

331. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodi-pine adding perindopril as required versus atenolol adding bendo-flumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre random­ized controlled trial. Lancet 2005;366:895–906. RT.

332. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a ran­domized controlled trial. JAMA 2003;290:2805–2816. RT.

333. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Interven­tion For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003. RT.

334. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HCMOSES Study Group. Morbidity and Mor­tality After Stroke. Eprosartan Compared with Nitrendipine for Second­ary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–1226. RT.

335. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N for the Jikei Heart Study group. Valsar-tan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431–1439. RT.

336. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. VALUE trial group. Outcomes in hypertensive patients at high cardiovas­cular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022–2031. RT.

337. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. Br Med J 2004;329:1248–1249. RV.

338. Volpe M, Mancia G, Trimarco B. Angiotensin receptor blockers and myo-cardial infarction: the importance of dosage. J Hypertens 2006;24: 1681–1682. RV.

339. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II recep­tor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26:2381–2386. MA.

340. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H. ONTARGET/TRANSCEND Investigators. Ration­ale, design, baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, their combination in high-risk patients: the Ongoing Telmisartan Alone, in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004;148:52–61. RT.

341. Dickstein K, Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbid­ity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002;360:752–760. RT.

342. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1896. RT.

343. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losar-tan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–1587. RT.

344. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545–1553. MA.

345. Hypertension: management of hypertension in adults in primary care NICE/BHS. GL. June 2006. wwww.nice.org.uk/CG034nice.org.uk/ CG034.

346. McInnes GT, Kjeldsen SE. Never mind the quality, feel the width–ALLHAT revisited. Blood Press 2004;13:330–334. RV.

347. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, Haywood LJ, Leenen FH, Margolis KL, Papademetriou V, Probstfield JL, Whelton PK, Habib GB. ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthali-done, amlodipine, and lisinopril. JAMA 2005;293:1595–1608. CT.

348. Cuspidi C, Muiesan ML, Valagussa L, Salvetti M, Di Biagio C, Agabiti-Rosei E, Magnani B, Zanchetti A. CATCH investigators. Compara­tive effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20:2293–2300. RT.

349. Jennings GL, McMullen JR. Left ventricular hypertrophy. Beyond the image and defining human cardiac phenotype in hypertension. J Hypertens 2007; in press. RV.

350. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003;115:41–46. MA.

351. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, Schuurman FH, Meyboom-de Jong B, Crijns HJ. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001;19:303–309. RT.

352. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT, Dahlof B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001;104:1248–1254. RT.

353. Zanchetti A, Ruilope LM, Cuspidi C, Macca G, Verschuren J, Kerselaers W. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study. J Hypertens 2001;19(Suppl 2):S92. (abstract). RT.

354. Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, Hennig M, Baurecht H, Parati G, Mancia G, Zanchetti A. ELSA Echocar-diographic Substudy Group. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and ateno-lol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005;23:1091–1098. CT.